[1] 彭劼. 慢性丙型肝炎的研究进展 [J]. 医学研究杂志 2008.doi:10.3969/j.issn.1673-548X.2008.03.003
[2] 唐小平, 钱可平, Johnson YN LAU, 袁小珍. HCV准种多样性及其与临床关系的研究 [J]. 中华实验和临床病毒学杂志 2001.doi:10.3760/cma.j.issn.1003-9279.2001.02.020
[3] 边静, 张锋, 赵红娜, Bian Jing, Zhang Feng, Zhao Hongna. 保定市普通人群丙型肝炎病毒感染的调查 [J]. 医学研究与教育 2010.doi:10.3969/j.issn.1674-490X.2010.03.020
[4] 程勇前, 聂青和, 周永兴, 黄晓峰, 罗红, 杨华光. 透射电镜及激光共聚焦技术观察体外丙型肝炎病毒感染的人胎盘滋养层细胞 [J]. 世界华人消化杂志 2003.doi:10.3969/j.issn.1009-3079.2003.02.006
[5] 郭振华, 景涛. 丙型肝炎病毒传播研究新进展 [J]. 临床消化病杂志 2005.doi:10.3870/j.issn.1005-541X.2005.02.017
[6] 杨东亮. 丙型肝炎的病毒学检测指标及其临床意义 [J]. 中华肝脏病杂志 2004.doi:10.3760/j.issn:1007-3418.2004.02.014
[7] 庄辉. 重视丙型肝炎的研究 [J]. 中华肝脏病杂志 2004.doi:10.3760/j.issn:1007-3418.2004.02.001
[8] 徐东平, 周先志, Xu Dong-ping, Zhou Xian-zhi. 丙型肝炎抗病毒治疗药物研究进展 [J]. 传染病信息 2008.doi:10.3969/j.issn.1007-8134.2008.04.006
[9] 贾因棠, 魏来, Jia YT, Wei L. 聚乙二醇化干扰素治疗慢性丙型肝炎的研究进展 [J]. 世界华人消化杂志 2005.doi:10.3969/j.issn.1009-3079.2005.11.017
[10] BOWEN D G, WALKER C M. The origin of quasispecies:cause orconsequence of chronic hepatitis C viral infection [J]. Journal of Hepatology 2005, 42(03).
[11] Kang SM, Choi SH, Park CY, Kim MH, Kim TK, Park JM, Koh MS, Kang HJ, Hwang SB. Monoclonal antibody recognizing N-terminal epitope of hepatitis C virus nonstructural 5B inhibits viral RNA replication. [J]. Journal of viral hepatitis 2008, 4(4).
[12] BEAULIEU P L, TSANTRIZOS Y S. Inhibitors of the HCV NS5B polymerase:new hope for the treatment of hepatitis C infections [J]. Current Opinion in Investigational Drugs 2004, 5(08).
[13] SIMMONDS P, BUKH J, COMBET C. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes [J]. Hepatology 2005, 42(04).
[14] Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. [J]. The Lancet infectious diseases 2005, 9(9).
[15] Slavenburg S, Verduyn-Lunel FM, Hermsen JT, Melchers WJ, te-Morsche RH, Drenth JP. Prevalence of hepatitis C in the general population in the Netherlands. [J]. Netherlands journal of medicine 2008, 1(1).
[16] Polizzotto MN, Wood EM, Ingham H, Keller AJ. Reducing the risk of transfusion-transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006. [J]. Transfusion: The Journal of the American Association of Blood Banks 2008, 1(1).
[17] Centers for Disease Control and Prevention(CDC). Hepatitis C virus transmission from an antibody-negntive organ and tissue donor-United States, 2000-2002 [J]. Morbidity and Mortality Weekly Report 2003, 52(13).
[18] Laperche S, Le Marrec N, Simon N, Bouchardeau F, Defer C, Maniez Montreuil M, Levayer T, Zappitelli JP, Lefrere JJ. [J]. Transfusion: The Journal of the American Association of Blood Banks 2003.
[19] Castillo I, Pardo M, Bartolome J, Ortiz Movilla N, Rodriguez Inigo E, Lucas Sd S, Salas C, Jimenez Heffernan JA, Perez Mota A, Graus J, Lopez Alcorocho JM, Carreno V. [J]. The Journal of Infectious Diseases 2004.
[20] Bartolome, J, Lopez-Alcorocho, JM, Castillo, I, Rodriguez-Inigo, E, Quiroga, JA, Palacios, R, Carreno, V. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C [J]. Journal of Virology 2007, 14(14).
[21] Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. [J]. Gut 2006, 9(9).
[22] GHANY M G, STRADER D B, THOMAS D L. Diagnosis, management, and treatment of hepatitis C:an update [J]. Hepatology 2009, 49(04).
[23] Vladimir Frecer, Martin Kabelac, Piergiuseppe De Nardi, Sabrina Pricl, Stanislav Miertus. [J]. Journal of molecular graphics & modelling 2004.
[24] Kukolj, G, McGibbon, GA, McKercher, G, Marquis, M, Lefebvre, S, Thauvette, L, Gauthier, J, Goulet, S, Poupart, MA, Beaulieu, PL. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase [J]. The Journal of Biological Chemistry 2005, 47(47). |
